Drug
Treprostinil palmitil inhalation powder (TPIP)
Status:
Phase 3
Condition:
Pulmonary Hypertension ILD
Intervention Type:
Inhaled Drug
Funder Type:
Industry
Drug Details
Treprostinil palmitil inhalation powder (TPIP) dilates blood vessels in the lungs, which decreases pulmonary vascular resistance and lessens the workload within the right side of the heart.
Study Purpose
This is a phase 3, randomized, double-blind, placebo-controlled, multi-center, and parallel clinical study to evaluate the safety and tolerability of TPIP in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).